Day: June 7, 2021

GR Silver Mining Reports Drill Results Including a High-grade Au-rich Polymetallic Vein from the Plomosas Mine Area

MotherlodeTV
Figure 1: Plomosas Mine Area: Large Epithermal System with New Discoveries (Drone image) (CNW Group/GR Silver Mining Ltd.)
Figure 1: Plomosas Mine Area: Large Epithermal System with New Discoveries (Drone image) (CNW Group/GR Silver Mining Ltd.)

GR Silver Mining Ltd. (TSXV: GRSL) (OTCQB: GRSLF) (FRANKFURT: GPE) (“GR Silver Mining” or the “Company”) – is pleased to report drill results in the northern portion of the Plomosas Mine Area. These results represent intersections of polymetallic (Ag-Au-Pb-Zn) hydrothermal breccia near the surface in unmined areas in the historic Plomosas Mine Area (Figure 1) at the Plomosas Silver Project (“Plomosas Project”) in Sinaloa, Mexico. read more

Ground Magnetic Survey Confirms and Expands Target Areas at Eloro Resources’ Iska Iska Silver-Tin Polymetallic Project, Bolivia

MotherlodeTV
ELO.V, Eloro, 321gold.com, Bob Moriarty, Bolivia, Iska Iska property,
Figure 1

Eloro Resources Ltd. (TSX-V: ELO; OTCQX: ELRRF FSE: P2QM) (“Eloro”, or the “Company”) is pleased to report results from its recently completely magnetics survey on the Company’s Iska Iska silver-tin polymetallic project in Potosi Department, southern Bolivia. A total of 181.5 linekm of magnetic data were collected on 50m spaced north-south lines on all of the accessible parts of the property. read more

Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Dosing is complete in first of three human clinical studies hoped to validate Lexaria’s patented technology for hypertension relief – Study tested an advanced “DehydraTECH™ 2.0” CBD formulation – Second human clinical study, HYPER-H21-2, to commence immediately
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule. read more